The market's misinterpretation of Nektar Therapeutics' $NKTR clinical results created an opportunity for those who missed the run. Now in correction mode, this stock will not fall below $50. $NKTR, Nektar Therapeutics / H1 Agree or disagree?Login to vote. Free to sign-up.